Prestige Consumer Healthcare Inc. · NYSE:PBH

Prestige Consumer Healthcare — Prestige Brands Holdings — Q2 FY2014 Earnings Presentation

23 slides from Prestige Consumer Healthcare's earnings presentation, Nov 7, 2013

  1. Slide 1: Review of Second Quarter F'14 Results

    P R E S T I G E B R A N D S S e c o n d Q u a r t e r F ’ 1 4 R e s u l t s 1 Review of Second Quarter F’14 Results Matt Mannelly, CEO & President Ron Lombardi, CFO November 7, 2013 Exhibit 99.2

  2. Slide 2: Safe Harbor Disclosure

    P R E S T I G E B R A N D S S e c o n d Q u a r t e r F ’ 1 4 R e s u l t s 2 This presentation contains certain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements about the Company’s growth strategies, investments in advertisi

  3. Slide 3: Agenda for Today's Discussion

    P R E S T I G E B R A N D S S e c o n d Q u a r t e r F ’ 1 4 R e s u l t s 3 1. Q2 FY2014: Performance Highlights 2. Q2 FY2014: Financial Overview 3. FY2014 Outlook and The Road Ahead Agenda for Today’s Discussion

  4. Slide 4: Our Corporate Mission

    P R E S T I G E B R A N D S S e c o n d Q u a r t e r F ’ 1 4 R e s u l t s 4 Our Corporate Mission To be the Best Mid-Sized, Public Company in the Consumer Health Care Market The following principles guide us in this endeavor:  deliver outstanding shareholder value through superior growth in sales

  5. Slide 5: Q2 FY2014: Performance Highlights

    P R E S T I G E B R A N D S S e c o n d Q u a r t e r F ’ 1 4 R e s u l t s 5 Q2 FY2014: Performance Highlights

  6. Slide 6: Second Quarter Highlights

    P R E S T I G E B R A N D S S e c o n d Q u a r t e r F ’ 1 4 R e s u l t s 6 Second Quarter Highlights  Strong financial performance: +11.9% Adjusted E.P.S. growth − Adjusted E.P.S.(1) of $0.47, up 11.9% versus prior year corresponding quarter − Continued deleveraging based on strong Cash Flow fro

  7. Slide 7: Q2: Revenue Growth Across the Portfolio

    P R E S T I G E B R A N D S S e c o n d Q u a r t e r F ’ 1 4 R e s u l t s 7 Q2: Revenue Growth Across the Portfolio Excludes the brands impacted by expected pediatrics return 5.0% 1.6% 4.5% 8.0%

  8. Slide 8: Focus on Headache Powders: Brand-Building Through Innovation

    P R E S T I G E B R A N D S S e c o n d Q u a r t e r F ’ 1 4 R e s u l t s 8 Focus on Headache Powders: Brand-Building Through Innovation and Creative Marketing & Advertising • An Innovation in Dose Form • Fast Liquid Action in a Good-Tasting Convenient New Package • No Other Product Like It • An I

  9. Slide 9: Sports Marketing and Marketing Programs Focused on Speed

    P R E S T I G E B R A N D S S e c o n d Q u a r t e r F ’ 1 4 R e s u l t s 9 Sports Marketing: Southeastern Conference Championship Sponsorship & Sampling Retail Partnerships, Sampling & Mobile Marketing Social Media to Engage Consumers Featured Retail Displays Print Media – FSI’s & Couponing TV/Ra

  10. Slide 10: Driving Goody's Headache Relief Shot through New Integrated Marketing

    P R E S T I G E B R A N D S S e c o n d Q u a r t e r F ’ 1 4 R e s u l t s 1 0 Driving Goody’s Headache Relief Shot through New integrated Marketing vehicles Goody’s Headache Relief Shot 500 Dale Jr “Fastest Fan” contest National Media Sampling Signage National Media Social investment Website PR Re

  11. Slide 11: C-Stores: A Strengthening Platform For PBH Brands

    P R E S T I G E B R A N D S S e c o n d Q u a r t e r F ’ 1 4 R e s u l t s 1 1 C-Stores: A Strengthening Platform For PBH Brands PBH Brands in C-Stores C-Store Customers The five Core OTC brands in C-Store grew almost 20% in Q2 vs. the prior year Southern C-Stores became our launch pad to expand di

  12. Slide 12: Prestige Brands Growth On-The-Go

    P R E S T I G E B R A N D S S e c o n d Q u a r t e r F ’ 1 4 R e s u l t s 1 2 Prestige Brands Growth On-The-Go At Airport News Stands At Gas Stations and C-Stores At Major Convenience Retailers

  13. Slide 13: Q2 FY2014: Financial Overview

    P R E S T I G E B R A N D S S e c o n d Q u a r t e r F ’ 1 4 R e s u l t s 1 3 Q2 FY2014: Financial Overview

  14. Slide 14: Summary Financial Performance

    P R E S T I G E B R A N D S S e c o n d Q u a r t e r F ’ 1 4 R e s u l t s 1 4 Summary Financial Performance Dollar values in millions, except per share data Notes: (1) These non-GAAP financial measures are reconciled to their most closely related GAAP financial measures in our earnings release in

  15. Slide 15: Q2 Consolidated Financial Summary

    P R E S T I G E B R A N D S S e c o n d Q u a r t e r F ’ 1 4 R e s u l t s 1 5  Net Revenue grew $2.6 million, or 1.6%, excluding results in prior year quarter from the divested Phazyme brand and the acquisition of Care this quarter – Excluding the Pediatrics portfolio, core OTC revenue growth of

  16. Slide 16: YTD Consolidated Financial Summary

    P R E S T I G E B R A N D S S e c o n d Q u a r t e r F ’ 1 4 R e s u l t s 1 6  Adjusted Net Revenue increased 0.7% over the prior year, with Revenue essentially flat, ($0.2) million or (0.1%) versus the prior year excluding the impact of the Care acquisition and Phazyme divestiture – Excluding th

  17. Slide 17: Net Income and E.P.S. Reconciliation

    P R E S T I G E B R A N D S S e c o n d Q u a r t e r F ’ 1 4 R e s u l t s 1 7 Net Income and E.P.S. Reconciliation Dollar values in millions, except per share data Note: These Non-GAAP financial measures are reconciled to their reported GAAP amounts in our Earnings Release in the “About Non-GAAP F

  18. Slide 18: Debt Profile & Financial Compliance

    P R E S T I G E B R A N D S S e c o n d Q u a r t e r F ’ 1 4 R e s u l t s 1 8 Debt Profile & Financial Compliance:  Total Net Debt at 9/30/13 of $958 million comprised of: – Cash on hand of $26.8 million – $438 million of term loan – $500 million of bonds – $47 million of revolver  Leverage rati

  19. Slide 19: Rapid Deleveraging Provides for Significant M&A Capacity

    P R E S T I G E B R A N D S S e c o n d Q u a r t e r F ’ 1 4 R e s u l t s 1 9 Rapid Deleveraging Provides for Significant M&A Capacity Dollar values in millions, unless otherwise noted Notes: (1) Leverage ratio reflects net debt / covenant defined EBITDA (2) Illustrative M&A capacity is based on a

  20. Slide 20: FY2014 Outlook and Road Ahead

    P R E S T I G E B R A N D S S e c o n d Q u a r t e r F ’ 1 4 R e s u l t s 2 0 FY2014 Outlook and Road Ahead

  21. Slide 21: FY Focus Remains Intact

    P R E S T I G E B R A N D S S e c o n d Q u a r t e r F ’ 1 4 R e s u l t s 2 1 FY 14 Focus Remains Intact  Stay the course in a transitional marketplace − Continue brand building investment in Core OTC portfolio • Continue to support new product launches through advertising and merchandising • New

  22. Slide 22: Our Confidence for Long-Term E.P.S. Guidance

    P R E S T I G E B R A N D S S e c o n d Q u a r t e r F ’ 1 4 R e s u l t s 2 2 Our confidence for Long-Term E.P.S. Guidance + +

  23. Slide 23: P R E S T I G E B R A N D S S e c o n d Q u a r t e r F ’ 1 4 R e s u l t s 2 3

    P R E S T I G E B R A N D S S e c o n d Q u a r t e r F ’ 1 4 R e s u l t s 2 3

Prestige Brands Holdings — Q2 FY2014 Earnings Presentation on 6ix